Zobrazeno 1 - 10
of 558
pro vyhledávání: '"Richard E, Clark"'
Autor:
Elena Karg, Christoph Baldow, Thomas Zerjatke, Richard E. Clark, Ingo Roeder, Artur C. Fassoni, Ingmar Glauche
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionDiscontinuation of tyrosine kinase inhibitor (TKI) treatment is emerging as the main therapy goal for Chronic Myeloid Leukemia (CML) patients. The DESTINY trial showed that TKI dose reduction prior to cessation can lead to an increased nu
Externí odkaz:
https://doaj.org/article/02f53142ebb54357bbd60724872348d6
Autor:
Richard E. Clark
Richard Clark's observation that “…media are mere vehicles that deliver instruction but do not influence student achievement any more than the truck that delivers our groceries causes changes in our nutrition” is as misunderstood today as it wa
Autor:
Nigel H. Russell, Robert K. Hills, Abin Thomas, Ian Thomas, Lars Kjeldsen, Mike Dennis, Charles Craddock, Sylvie Freeman, Richard E. Clark, Alan K. Burnett
Publikováno v:
Haematologica, Vol 107, Iss 7 (2021)
Reduced intensity conditioning (RIC) transplantation is increasingly offered to older patients with acute myeloblastic leukemia. We have previously shown that a RIC allograft, particularly from a sibling donor, is beneficial in intermediate-risk pati
Externí odkaz:
https://doaj.org/article/ea905c516b5547eebbeabeafe8d82f35
Autor:
Claire M. Lucas, Laura J. Scott, Natasha Carmell, Alison K. Holcroft, Robert K. Hills, Alan K. Burnett, Richard E. Clark
Publikováno v:
Blood Advances, Vol 2, Iss 9, Pp 964-968 (2018)
Externí odkaz:
https://doaj.org/article/cebec7353bac4119b43b94a1922ee01c
Autor:
Ross Kinstrie, Dimitris Karamitros, Nicolas Goardon, Heather Morrison, Mike Hamblin, Lisa Robinson, Richard E. Clark, Mhairi Copland, Paresh Vyas
Publikováno v:
Blood Advances, Vol 1, Iss 3, Pp 160-169 (2016)
Abstract: Chronic myeloid leukemia (CML) is an excellent model of the multistep processes in cancer. Initiating BCR-ABL mutations are required for the initial phase of the disease (chronic phase, CP-CML). Some CP-CML patients acquire additional mutat
Externí odkaz:
https://doaj.org/article/cc5b84916719460691ec82068e49351a
Autor:
Dragana Milojkovic, Alexander R. Lyon, Priyanka Mehta, Evangelia Dimitriadou, Satarupa Choudhuri, Charlotte Manisty, Nick Cheshire, Kirsty Crozier, Nanda Basker, Karim Amer, Simon Purcell, Susan Tan, Richard E. Clark
Publikováno v:
European Journal of Haematology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::88cb9e08a95fea16a38c4ab9e66aa3a2
https://doi.org/10.1111/ejh.13983
https://doi.org/10.1111/ejh.13983
Autor:
Sonja Loges, Tessa L. Holyoake, G. Vignir Helgason, Carsten Bokemeyer, Klaus Pantel, Andreas Hochhaus, Peter Carmeliet, Tim H. Brümmendorf, Peter Vandenberghe, Subir Mitra, Alexander Schultze, Steffen Koschmieder, Richard E. Clark, Stephen Rankin, Janna L. Velthaus, Philippe Schafhausen, Gunhild von Amsberg, Thomas Ernst, Rebecca Mitchell, Heather Jørgensen, Robert Erdmann, Isabel Ben-Batalla
Purpose: BCR-ABL kinase inhibitors are employed successfully for chronic myeloid leukemia (CML) treatment. However, resistant disease and persistence of BCR-ABL1–independent leukemia stem and progenitor cells (LSPC) remain clinical challenges. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c4c9f65def4c57a65d58ae92abc93d8
https://doi.org/10.1158/1078-0432.c.6525134.v1
https://doi.org/10.1158/1078-0432.c.6525134.v1
Autor:
Jukka Westermarck, Maija Itälä-Remes, Claire M. Lucas, Venkata Kumari Bachanaboyina, Laura L. Elo, Richard E. Clark, Veli-Matti Kähäri, Tea Ammunét, Srikar G. Nagelli, Eliisa Löyttyniemi, Urpu Salmenniemi, Taru Varila, Karolina Pavic, Eleonora Mäkelä
Supplementary tables S1-S5 and supplementary figures S1-S5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::719326290e46c0e1fbf0e57e719f057d
https://doi.org/10.1158/1078-0432.22479393.v1
https://doi.org/10.1158/1078-0432.22479393.v1
Autor:
Sonja Loges, Tessa L. Holyoake, G. Vignir Helgason, Carsten Bokemeyer, Klaus Pantel, Andreas Hochhaus, Peter Carmeliet, Tim H. Brümmendorf, Peter Vandenberghe, Subir Mitra, Alexander Schultze, Steffen Koschmieder, Richard E. Clark, Stephen Rankin, Janna L. Velthaus, Philippe Schafhausen, Gunhild von Amsberg, Thomas Ernst, Rebecca Mitchell, Heather Jørgensen, Robert Erdmann, Isabel Ben-Batalla
Figure S1. Inhibition of Axl by shRNA. Figure S2. Assessment of half maximal inhibitory concentration (IC50) for BGB324 in human CD34+ cells from healthy donors. Figure S3. Treatment with BGB324 increased apoptosis and decreased proliferation of CML
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5afe9081732bbaa5bc72c766273976ad
https://doi.org/10.1158/1078-0432.22462538
https://doi.org/10.1158/1078-0432.22462538
Autor:
Jukka Westermarck, Maija Itälä-Remes, Claire M. Lucas, Venkata Kumari Bachanaboyina, Laura L. Elo, Richard E. Clark, Veli-Matti Kähäri, Tea Ammunét, Srikar G. Nagelli, Eliisa Löyttyniemi, Urpu Salmenniemi, Taru Varila, Karolina Pavic, Eleonora Mäkelä
Purpose:Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein that inhibits the tumor suppressor PP2A-B56α. However, CIP2A mRNA variants remain uncharacterized. Here, we report the discovery of a CIP2A splicing variant, novel CIP2A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fafacee52720caa917ca11aea05890f
https://doi.org/10.1158/1078-0432.c.6530211
https://doi.org/10.1158/1078-0432.c.6530211